Skip to main content
Clinical Trials/NCT02578355
NCT02578355
Not yet recruiting
Not Applicable

National Plaque Registry and Database

Semmelweis University Heart and Vascular Center11 sites in 1 country20,000 target enrollmentSeptember 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atherosclerosis
Sponsor
Semmelweis University Heart and Vascular Center
Enrollment
20000
Locations
11
Primary Endpoint
All cause death
Status
Not yet recruiting
Last Updated
9 years ago

Overview

Brief Summary

The ultimate goal of this project is to develop a risk score to identify patients with vulnerable coronary atherosclerotic plaques, who are prone to suffer acute coronary syndrome. Early identification of vulnerable plaques may have an enormous impact on public health through primary and secondary prevention of acute myocardial infarction.

Investigators hypothesize that a risk score that incorporates non-invasive coronary CT imaging (calcium score and/or coronary CTA) in combination with clinical characteristics (classical risk prediction models) will improve the identification of patients who are at highest risk to suffer myocardial infarction or sudden cardiac death.

The overall goal of the OPeRA project is to develop, implement and validate a novel risk assessment tool based on image markers and clinical characteristics to identify patients who are at increased risk to suffer myocardial infarction or sudden cardiac death.

Detailed Description

The primary goals of OPeRA consortium: To develop a national coronary CTA registry with the collaboration of all major cardiac CT centers of Hungary (Országos Plaque Regiszter és Adatbázis - NatiOnal Plaque Registry and DAtabase, OPeRA). 1. To develop a novel risk assessment tool (OPeRA score) based on image markers and clinical characteristics. 2. To identify and validate novel vulnerable coronary plaque image markers and assess their prognostic value. Secondary goals: 1. To develop a standardized and structured, national coronary CTA reporting system. 2. To establish a national quality control system that monitors the quantity of iodinated contrast agent and the patients' radiation dose.

Registry
clinicaltrials.gov
Start Date
September 2016
End Date
December 2030
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Semmelweis University Heart and Vascular Center
Responsible Party
Principal Investigator
Principal Investigator

Pál Maurovich-Horvat

Assistant Professor

Semmelweis University Heart and Vascular Center

Eligibility Criteria

Inclusion Criteria

  • Age \> 18 years
  • Subject providing written informed consent
  • Scheduled to undergo a clinically indicated coronary CTA

Exclusion Criteria

  • Age \<18 years
  • Suspicion of acute coronary syndrome (acute myocardial infarction and unstable angina)
  • Recent prior myocardial infarction within 30 days prior to coronary CTA or between coronary CTA and ICA
  • Pregnancy or unknown pregnancy status in subject of childbearing potential
  • Subject requires an emergent procedure
  • Evidence of ongoing or active clinical instability, including acute chest pain (sudden onset), cardiogenic shock, unstable blood pressure with systolic blood pressure \<90 mmHg, and severe congestive heart failure (NYHA III or IV) or acute pulmonary edema
  • Inability to comply with study procedures

Outcomes

Primary Outcomes

All cause death

Time Frame: 10 years

Secondary Outcomes

  • CAD-related hospitalization(10 years)
  • Unstable angina(10 years)
  • Myocardial infarction(10 years)
  • Target vessel revascularization(10 years)

Study Sites (11)

Loading locations...

Similar Trials